Similarly, in each functional classification system of TP53 alterations, best ORR (Supplemental Fig. 7a) and survival features (Fig. 3a–h) were comparable in cases with different risk levels, suggesting CAR19/22 T-cell treatment overcame the negative effects of TP53 disruption in aggressive B-cell lymphoma. The gene discussed is TP53; the disease is B-cell non-Hodgkin lymphoma.